L-Isoleucine
|
Basic information |
| Metabolite name | L-Isoleucine |
 | HMDB0000172 |
 |
C00407 |
 |
6306 |
| Synonyms | Iso-leucine; |
| No. of studies | 64 |
|
Basic information |
| Metabolite name | L-Isoleucine |
| HMDB0000172 |
|
C00407 |
|
6306 |
| Synonyms | Iso-leucine; |
| No. of studies | 64 |
|
Relationship between L-Isoleucine and depression (count: 64) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Thalamus | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M006 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Up |
| Study M015 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M015 | Type2 | CUMS + Xiaoyaosan Nan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M015 | Type2 | CUMS + Xiaoyaosan Bei group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Up |
| Study M051 | Type3 | fluoxetine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M054 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M068 | Type2 | CUMS + citalopram group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M078 | Type1 | CORT model group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M093 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M093 | Type2 | paroxetine group vs. baseline | Serum | Human | Down |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | Wistar rat | Up |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Prefrontal cortex | Wistar rat | Up |
| Study M098 | Type1 | depressed group vs. control group | Peripheral blood mononuclear cell | Human | Down |
| Study M1042 | Type1 | CUMS + MCAO group vs. MCAO group | Faece | Sprague-Dawley rat | Down |
| Study M1066 | Type1 | CUMS group vs. control group | Kidney | Sprague-Dawley rat | Up |
| Study M1066 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Kidney | Sprague-Dawley rat | Down |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
| Study M1076 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M1093 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6N mouse | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, female offspring | Faece | ICR mouse | Down |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M132 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M132 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M457 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M457 | Type2 | CUMS + D6 doses of PBR group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M486 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
| Study M510 | Type1 | HSD group vs. control group | Urine | Human | Up |
| Study M520 | Type1 | depressive HCV group vs. non-depressive HCV group | Plasma | Human | Down |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Unknown |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + low dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M547 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M552 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + high dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + low dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + augmentation treatment group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + median dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Plasma | Human | Unknown |
| Study M584 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + low dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + high dose of negative control treatment group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + low dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M589 | Type1 | current depression group vs. control group | Plasma | Human | Up |
| Study M591 | Type1 | LPS group vs. control group | Plasma | CD-1 mouse | Up |
| Study M592 | Type1 | CUMS group vs. control group, NMR | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M610 | Type1 | CUMS group vs. control group | Kidney | Sprague-Dawley rat | Down |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M629 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M633 | Type2 | corticosterone + Chrysanthemum morifolium group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Down |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M721 | Type1 | CUMS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Serum | C57BL/6J mouse | Down |
| Study M779 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M779 | Type2 | depression group, post vs. before treatment | Plasma | Human | Down |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M809 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M809 | Type2 | CUMS + Milletia speciosa Champ group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + low dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M821 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M827 | Type1 | CUMS + middle dose of Millettia speciosa Champ group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M827 | Type1 | CUMS + low dose of Millettia speciosa Champ group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M827 | Type1 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M827 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M847 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M847 | Type2 | CUMS + Bupleuri Radix group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M870 | Type2 | CRS + middle dose of Jia Wei Xiao Yao San group vs. CRS group | Brain | C57BL/6 mouse | Up |
| Study M877 | Type1 | depressed COPD group vs. COPD group | Plasma | Human | Down |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M918 | Type1 | methamphetamine group vs. control group | Serum | C57BL/6 mouse | Up |
| Study M924 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M924 | Type2 | CUMS + aerobic exercise group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M943 | Type2 | CUMS + fluoxetine group vs. CUMS group | Liver | ICR mouse | Down |
| Study M943 | Type2 | CUMS + high dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Down |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Down |
| Study M950 | Type2 | probiotic group vs. placebo group | Faece | Human | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M975 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M975 | Type2 | CUMS + fluoxetine group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M975 | Type2 | CUMS + middle dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M975 | Type2 | CUMS + high dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Faece | Sprague-Dawley rat | Up |